معرفی
Gregg C Fonarow is a Clinical Professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA). His research focuses on cardiology, heart failure management, cardiovascular outcomes, and the intersection of diabetes with cardiovascular risk. He leads the NIH-funded ACTION trial investigating exercise outcomes in heart failure patients.
Research interests span guideline-directed therapies, pharmacotherapy optimization, healthcare economics in heart failure, and disparities in cardiovascular care. His work emphasizes real-world evidence, clinical guidelines implementation, and predictive modeling for conditions like transthyretin amyloid cardiomyopathy and acute coronary syndromes.
Publications predominantly analyze trends in cardiovascular hospitalizations, renal outcomes in heart failure, and innovative therapies (e.g., SGLT2 inhibitors, GLP-1 agonists). Key themes include risk stratification, quality improvement, and cost-effectiveness across diverse populations, including older adults and those with comorbid diabetes.